Biotech Stocks

Leo Pharma to license Tanabe’s rare disease drug for pain with sun exposure

Endpoints News Aug 18, 2026 $435M

Leo Pharma said it will pay Japan’s Tanabe Pharma up to $435 million in upfront and near-term payments to license an oral drug for a pair of genetic light-sensitive skin diseases. The Danish biotech will ...

Discussion

Sign in to join the discussion. Comments loading…